Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté

Erythrocyte Transfusion for All Conditions Clinical Trial

— STeF-BFC  

Official title:

Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02852993
• Other study ID #: P/2013/176
• Status: Completed
• Phase: N/A
• First received: July 29, 2016
• Last updated: August 1, 2016
• Start date: September 2013
• Est. completion date: June 2015

Study information

• Verified date: July 2016
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: National Consultative Ethics Committee for Health and Life SciencesFrance: French Data Protection AuthorityFrance: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource.

The investigators aim to study the impact of donor and RBC characteristics on patient survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16099
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 and over

• Erythrocyte Transfusion between 2007 and 2011

• Performed at the University Hospital of Besançon or Dijon

Exclusion Criteria:

• Transfusion of any blood product prior to January 1st, 2007

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Erythrocyte Transfusion for All Conditions

Locations

Country	Name	City	State
France	Centre d'Investigation Clinique, CHU de Besançon	Besançon
France	Département d'information Médicale, CHU Dijon	Dijon

Sponsors (3)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon	Centre Hospitalier Universitaire de Dijon, Etablissement Français du Sang

Country where clinical trial is conducted

France, 

References & Publications (1)

Desmarets M, Bardiaux L, Benzenine E, Dussaucy A, Binda D, Tiberghien P, Quantin C, Monnet E. Effect of storage time and donor sex of transfused red blood cells on 1-year survival in patients undergoing cardiac surgery: an observational study. Transfusion — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival		12 months	Yes